PeptiSystems supports Servier’s first step into in-house oligonucleotide synthesis

Uppsala, Sweden – 30 September 2025

PeptiSystems has delivered an OligoNavigator synthesizer to Servier, marking an important milestone as the global pharmaceutical group takes its first step into in-house oligonucleotide synthesis.

Servier is an independent global pharmaceutical group headquartered in France, focused on research and development in oncology, cardiometabolism, neuroscience, and immuno-inflammatory diseases. The company has broadened its research to include new therapeutic modalities, such as oligonucleotides.

PeptiSystems’ fully automated OligoNavigator synthesizer supports precise and efficient oligonucleotide process development and manufacturing. Built for research and process development, it helps scientists advance oligonucleotide synthesis, an area of growing significance in modern drug discovery.

“This collaboration illustrates how leading pharmaceutical organizations are strengthening their capabilities in oligonucleotide development through next-generation manufacturing,” says Karin Granath, CEO of PeptiSystems. “We are delighted to support Servier on this journey and to contribute to their continued innovation.”

The collaboration with Servier underlines PeptiSystems’ expanding role as a trusted technology partner for organizations advancing peptide and oligonucleotide drug development worldwide.